Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs. Twice Daily Dosing of Flomax- A 3 Month Retrospective Efficacy Analysis

This study has been completed.
Information provided by:
Dattoli Cancer Center and Brachytherapy Research Institute Identifier:
First received: December 6, 2005
Last updated: NA
Last verified: November 2005
History: No changes posted

In the past ten years, newer drugs with more selective affinity for the alpha-receptor have been introduced. Alfuzosin (Uroxatral) and Tamulosin(Flomax are two second generation alpha-blockers. In the course of our clinical proctice, both drugs have been used routinely. This retrospective comparison is intended to be a priliminary comparison of their effectiveness and side effects.

Prostate Cancer Patients Undergoing External Radiation and Seed Implantation

Study Type: Observational
Study Design: Observational Model: Defined Population
Time Perspective: Longitudinal
Official Title: Palladium-103 Seed Implant and Single Daily Dosing of Uroxatral Vs Twice Daily Dosing of Flomax-A 3 Month Retrospective Efficacy Analysis

Resource links provided by NLM:

Further study details as provided by Dattoli Cancer Center and Brachytherapy Research Institute:

Estimated Enrollment: 60
Study Start Date: November 2005
Estimated Study Completion Date: November 2005

Ages Eligible for Study:   45 Years to 80 Years
Genders Eligible for Study:   Male

Inclusion Criteria:

  • Males age 45-80 years
  • Diagnosis of prostate cancer
  • Status post IMRT and Palladium-103 seed implantation and initiated alpha blocker therapy with alfuzosin10mg daily or tamulosin 0.4mg bid at time of seed implantation
  • Baseline AUA score< or =12
  • May be on antiandrogenand/or alpha reductase therapy
  • Patients receiving IMRT followed by Palladium-103 Brachytherapy implantation as the primary therapy for prostate cancer with curatives intent -

Exclusion Criteria:

  • History of insulin-dependent diabetes
  • Uncontrolled hypertention
  • History of symptomtic hypotension (including syncope and dizziness)
  • Pre-existing obstructive uropathy based on history of BPH and or Acute Urinary Retention
  • Pre-existing prostatitis either continuous or intermittent
  • Concurrent use of any other anticholinergics
  • previous or concurrent usage of LHRH agonist
  Contacts and Locations
Please refer to this study by its identifier: NCT00264017

United States, Florida
Dattoli Cancer Center and Brachytherapy Research Institute
Sarasota, Florida, United States, 34237
Sponsors and Collaborators
Dattoli Cancer Center and Brachytherapy Research Institute
Principal Investigator: Michael J Dattoli, MD Dattoli Cancer Center and Brachytherapy Research Institute
  More Information

No publications provided Identifier: NCT00264017     History of Changes
Other Study ID Numbers: L0087
Study First Received: December 6, 2005
Last Updated: December 6, 2005
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Adrenergic alpha-1 Receptor Antagonists
Adrenergic alpha-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs processed this record on April 17, 2014